Mipomersen ( DrugBank: Mipomersen )


1 disease
IDDisease name (Link within this page)Number of trials
79Homozygous familial hypercholesterolemia1

79. Homozygous familial hypercholesterolemia


Clinical trials : 142 Drugs : 114 - (DrugBank : 29) / Drug target genes : 9 - Drug target pathways : 18
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00607373
(ClinicalTrials.gov)
July 200722/1/2008Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial HypercholesterolemiaA Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen as Add-on Therapy in Homozygous Familial Hypercholesterolemia SubjectsLipid Metabolism, Inborn Errors;Hypercholesterolemia, Autosomal Dominant;Hyperlipidemias;Metabolic Diseases;Hyperlipoproteinemia Type II;Metabolism, Inborn Errors;Genetic Diseases, Inborn;Infant, Newborn, Diseases;Metabolic Disorder;Congenital Abnormalities;Hypercholesterolemia;Hyperlipoproteinemias;Dyslipidemias;Lipid Metabolism DisordersDrug: mipomersen;Drug: PlaceboKastle Therapeutics, LLCIonis Pharmaceuticals, Inc.Completed12 YearsN/AAll51Phase 3United States;Brazil;Canada;Singapore;South Africa;Taiwan;United Kingdom;Netherlands